SILO PHARMA, INC. Financing Receivables Before Allowance For Credit Loss Average Amount Outstanding
SILO PHARMA, INC. (SILO) reported Financing Receivables Before Allowance For Credit Loss Average Amount Outstanding of $69.60 thousand for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Notes › Financial Services › Banking and Thrift
us-gaap:FinancingReceivablesBeforeAllowanceForCreditLossAverageAmountOutstanding · last filed 2023-11-13
- SILO PHARMA, INC. financing receivables before allowance for credit loss average amount outstanding for the quarter ending 2023-09-30 was $1.21K.
- SILO PHARMA, INC. financing receivables before allowance for credit loss average amount outstanding for the quarter ending 2023-06-30 was $1.20K.
- SILO PHARMA, INC. financing receivables before allowance for credit loss average amount outstanding for the quarter ending 2023-03-31 was $67.19K.
- SILO PHARMA, INC. financing receivables before allowance for credit loss average amount outstanding for fiscal 2021 was $61.21K.
| Period end | Financing Receivables Before Allowance For Credit Loss Average Amount Outstanding 3 month | Financing Receivables Before Allowance For Credit Loss Average Amount Outstanding 6 month | Financing Receivables Before Allowance For Credit Loss Average Amount Outstanding 9 month | Financing Receivables Before Allowance For Credit Loss Average Amount Outstanding 12 month |
|---|---|---|---|---|
| 2023-09-30 | $1.21K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $2.41K derived: sum of 2 quarters · filed 2023-11-13 | $69.60K 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $1.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $68.39K 10-Q · filed 2023-08-11 | ||
| 2023-03-31 | $67.19K 10-Q · filed 2023-05-12 | |||
| 2022-12-31 | $66.01K 10-Q · filed 2023-11-13 | |||
| 2021-12-31 | $61.21K 10-K · filed 2023-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |